New drug combo aims to shrink Hard-to-Operate ovarian tumors
Disease control
Not yet recruiting
This study tests two drug combinations (fluzoparib plus famitinib or fluzoparib plus SHR-1701) given before surgery to shrink advanced ovarian cancer in 104 women whose tumors cannot be fully removed right away. The goal is to see how well these treatments work and how safe they …
Phase: PHASE2 • Sponsor: Qinglei Gao • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC